Evidence behind pregnancy warnings and the difference between topical and oral minoxidil.
The Article in 30 Seconds
The Question: Women are advised to avoid minoxidil during pregnancy. Does this mean fetal harm is proven, and must every woman using it practise contraception?
What We Know: A few concerning reports exist, but topical minoxidil has not been established as a human teratogen. Pregnancy warnings largely reflect uncertainty.
My Verdict: There is no convincing evidence that topical minoxidil causes fetal harm, but its safety during pregnancy remains unestablished. Recommendations against its use are therefore largely precautionary. Routine contraception is not necessary solely because a woman uses topical minoxidil, although pregnancy-related counselling is appropriate. Topical use during established breastfeeding may be acceptable with precautions. Oral minoxidil warrants greater caution in both circumstances.
Women prescribed minoxidil for hair loss are often told to avoid it during pregnancy. Is this the right advice?
Should we also advise every woman of childbearing age using topical minoxidil not to become pregnant?
In my clinical practice, I have never needed to initiate treatment for hair loss during pregnancy. Hormonal changes often reduce hair shedding, although hair loss can certainly occur. Postpartum shedding is a much more familiar complaint. In most pregnancies, treatment for pattern hair loss can reasonably wait.
What does the pregnancy evidence show?
A few isolated case reports have described fetal abnormalities following maternal minoxidil exposure, including topical 2% minoxidil. However, these anecdotal observations do not establish causation, as other medications, underlying conditions or unrelated factors may have contributed. Neonatal hypertrichosis has also been reported, although excessive hair growth developing after birth may result from direct skin-to-skin transfer of topical minoxidil from the mother or another caregiver. Animal studies have raised reproductive safety concerns, but these effects were generally observed at systemic exposures substantially exceeding those expected with routine topical treatment. In humans, only approximately 1–2% of minoxidil applied to an intact scalp is systemically absorbed, and comparable high systemic exposures have not been demonstrated with normal topical use. It is reassuring that an observational study reported no apparent increase in adverse pregnancy outcomes, but the available details are insufficient to exclude uncommon risks.
The recommendation to avoid topical minoxidil during pregnancy is therefore largely precautionary: safety has not been demonstrated, and a potential risk cannot be excluded. This is reasonable for an elective treatment, although describing minoxidil as a proven human teratogen would overstate the evidence.
Does topical minoxidil require contraception?
UK topical minoxidil product information says it should not be used during pregnancy, but does not specifically instruct all women of reproductive age to use contraception. The British Association of Dermatologists advises avoiding it when planning pregnancy.
In my clinical practice, I do not routinely advise contraception solely because a woman is using topical minoxidil. Indeed, topical minoxidil prescribing information does not explicitly require contraception. However, it recommends avoiding treatment during pregnancy. It would therefore be reasonable to advise discontinuation when pregnancy is planned or recognised, while explaining that inadvertent exposure does not establish fetal harm.
What about breastfeeding?
Topical minoxidil product information advises against use during breastfeeding. However, LactMed, the US National Library of Medicine’s specialist database, considers topical minoxidil acceptable once breastfeeding is established, while acknowledging that supporting evidence is sparse.
One breastfed premature infant developed transient excessive facial hair during maternal topical use, although causation was uncertain and direct infant contact with minoxidil used may have been responsible.
Topical treatment may therefore be considered selectively during established breastfeeding, with precautions to prevent infant contact with treated skin or hair. Greater caution is appropriate for newborn and premature infants.
Oral minoxidil: Greater caution is justified
Oral minoxidil produces considerably greater systemic exposure and has been detected in breast milk. UK prescribing information advises against oral minoxidil during pregnancy and in women of childbearing potential who are not using contraception.
For low-dose oral minoxidil prescribed for hair loss, effective contraception should be advised, and treatment should generally be avoided during pregnancy and breastfeeding. The human evidence of harm remains limited, but the greater systemic exposure and elective indication justify a more cautious approach.
Legal Implications and Practical Conclusions
Topical minoxidil is not recommended during pregnancy primarily because adequate safety evidence is lacking, rather than because fetal harm has been established.
Its prescribing information does not explicitly require contraception, and there is no established minoxidil-specific legal obligation to routinely advise contraception. A product warning is not automatically a legal prohibition. Nevertheless, explaining the pregnancy precaution is prudent clinical practice.
However, prescribing minoxidil during an established pregnancy, contrary to product recommendations, could expose a doctor to a medical-negligence complaint if an adverse outcome occurs. Liability would depend on whether the doctor exercised reasonable professional care and whether the alleged negligence caused harm. The mere occurrence of a congenital abnormality would not establish negligence or causation.
During established breastfeeding, topical minoxidil may be considered with appropriate precautions. Oral minoxidil warrants greater caution, including contraception advice and generally avoiding its use for hair loss during pregnancy and breastfeeding.
References and Further Reading
Smorlesi C, et al. Topically applied minoxidil may cause fetal malformation: a case report. Birth Defects Res A Clin Mol Teratol. 2003;67:997–1001. DOI.
Shapiro J. Safety of topical minoxidil solution: a one-year, prospective, observational study. J Cutan Med Surg. 2003;7:322–329. DOI.
Regaine for Women Once a Day Scalp Foam 5%. UK Summary of Product Characteristics. Product information.
British Association of Dermatologists. Female Pattern Hair Loss. Patient information, updated October 2024. BAD guidance.
US National Library of Medicine. Minoxidil: Drugs and Lactation Database (LactMed). Updated May 2026. LactMed.
Minoxidil 5 mg Tablets. UK Summary of Product Characteristics. Oral minoxidil prescribing information.
General Medical Council. Good Practice in Prescribing: Prescribing Unlicensed Medicines. GMC guidance.